Anhui Huibang Bioengineering Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Anhui Huibang Bioengineering Co., Ltd. - overview
Established
2013
Location
Hefei, Anhui, China
Primary Industry
Biotechnology
About
Established in 2013 and based in Hefei, China, Anhui Huibang Bioengineering Co. , Ltd. is a biotech company that focuses on the development of in vitro diagnostic reagents. In 2016, the company launched a urine iodine quantitative analysis system.
In 2017, the company established a subsidiary Hefei Huibang Biotechnology. In 2019, the company was successfully listed in the Anhui Equity Custody and Trading Center with the listing code: 630215. The company engages in the development of in vitro diagnostic reagents. Its main products include tumor diagnostic reagents, maternal and child health diagnostic reagents, cardiovascular disease detection reagents, and POCT diagnostic reagents.
The non-invasive detection system for diabetic kidney disease provides renal biopsy, urine microalbumin and urine haptoglobin and other services.
Current Investors
Milestone Asset Management, SAIF Partners, Keyin Fund
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Diagnostic Equipment, Pharmaceutical Research & Development
Website
www.hbswgc.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.